Definitive Contract 75N91025C00024
Award Date
9/5/25
Potential Completion Date
9/4/27
Potential Value
$3M
Federal Agency
National Cancer Institute
Awardee
Continuity Biosciences, LLC
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Cary, NC 27513, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
16
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase II Action
Primary Consortia Member
Not listed
Similar Awards
This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...
The U.S. National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Phase I contract to Isola Therapeutics Inc., a for-profit small business, for the project "Drug Delivery by Endoesophageal Lavage (EEL) to Treat Esophageal Cancer". The $455,000 fixed-price contract has a period of performance through March 14, 2025. This award was made under the NCI's SBIR program, which aims to stimulate technological innovation, strengthen the role of small businesses in...
The National Cancer Institute (NCI) awarded a $353,102 Firm Fixed Price contract to Angstrom Research Inc., a self-certified small disadvantaged business, for a Phase I SBIR (Small Business Innovation Research) Concept Award. The contract, identified as 75N91024C00012, is part of the NCI's SBIR program and is focused on the development of innovative therapeutic technologies, devices, or diagnostics for the treatment, detection, and diagnosis of Pediatric Cancers and/or Rare Cancers. This is a...
This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Lodestone Biomedical LLC, a small business. The contract, valued at $2,050,000, is for the development of "INTRATUMORAL BIOSENSING FOR IN VIVO PHARMACOTYPING" technology. The contract has a firm fixed price pricing structure and a completion date of September 18, 2024. This SBIR Phase II award is part of the NCI's research and development...
This $399,987 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Cancer Institute (NCI), a part of the National Institutes of Health (NIH), to Care Progress LLC, a small business limited liability company. The contract supports the development of cancer clinical trials recruitment and retention tools for participant engagement, as described in the original SBIR solicitation. The solicitation sought proposals for SBIR Phase I and Phase II contracts to conduct...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...
<p>The National Cancer Institute (NCI), a civilian federal agency, awarded a Small Business Innovation Research (SBIR) Phase I contract to Shuttle Pharmaceuticals, Inc., a for-profit subchapter S corporation. The $224,687.00 firm-fixed-price contract, awarded on September 19, 2016, is for the SBIR PHASE I TOPIC 352 CELL-BASED MODELS FOR PROSTATE CANCER HEALTH DISPARITY RESEARCH project, with a planned completion date of June 18, 2017. This contract was set aside for small businesses.</p>
This $400,000 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Amplifidx Inc., a woman-owned small business. The contract supports the development of cancer prevention and diagnosis technologies for low-resource settings over a two-year period. This award aligns with NCI's mission to support innovative medical device research and development by small businesses. As a SBIR...
This is a $300,000 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Coordination Pharmaceuticals Inc., a small business. The contract is for the detection, diagnosis, treatment, prevention, and research of pediatric cancers and/or rare cancers. It was awarded under a Small Business Innovation Research (SBIR) Concept Award Program, which is a "Phase 0" pilot program intended to encourage small businesses to develop innovative and...
The Department of Health and Human Services' National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Pact & Health LLC, a for-profit limited liability company located in Branford, Connecticut. The contract, awarded on September 11, 2019, has a potential value of $299,799.00 and is for the development of a versatile radiation-triggered phosphor platform for localized anti-cancer therapy. The contract is a...